MedTrace Logo

A Retrospective Analysis of Magnetic Resonance Imaging Data for Breast Cancer Screening in the Open Consortium for Decentralized Medical Artificial Intelligence

NCT05698056 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 25000

Last updated 2024-02-28

No results posted yet for this study

Summary

ODELIA is a project that aims to improve breast cancer detection in magnetic resonance imaging by utilizing artificial intelligence and swarm learning (MRI). The project will create an open-source swarm learning software framework that will be used to train AI models for breast cancer detection. These models' performance will be compared to that of conventional AI models, and the results will be used to assess the effectiveness of swarm learning in improving the accuracy and robustness of AI models. The project will use retrospective, anonymized breast MRI datasets with manual ground truth labels for cancer presence. The study is not associated with any patient treatment or intervention. The project's goal is to provide evidence of the clinical benefits of swarm learning in the context of breast cancer screening, such as accelerated development, improved performance, and robust generalizability.

Conditions

Interventions

OTHER

No intervention.

No intervention.

Sponsors & Collaborators

  • European Institute for Biomedical Imaging Research (EIBIR), Austria

    collaborator UNKNOWN

  • University Hospital, Aachen

    collaborator OTHER

  • Vall d'Hebron Institute of Oncology

    collaborator OTHER

  • Mitera Hospital

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • Ribera Salud Hospitals, Spain

    collaborator UNKNOWN

  • Fraunhofer Institute for Digital Medicine (MEVIS), Germany

    collaborator UNKNOWN

  • University Hospital, Zürich

    collaborator OTHER

  • Cambridge University Hospitals NHS Foundation Trust

    collaborator OTHER

  • Technische Universität Dresden

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05698056 on ClinicalTrials.gov